Search Results - "PETERS, William P"

Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment by Augustine, Christina K, Yoshimoto, Yasunori, Gupta, Mukur, Zipfel, Patricia A, Selim, M Angelica, Febbo, Phillip, Pendergast, Ann Marie, Peters, William P, Tyler, Douglas S

“…Malignant transformation in melanoma is characterized by a phenotype "switch" from E- to N-cadherin, which is associated with increased motility and…”
Get full text

Associations Between Drug Metabolism Genotype, Chemotherapy Pharmacokinetics, and Overall Survival in Patients With Breast Cancer by PETROS, William P, HOPKINS, Penelope J, SPRUILL, Susan, BROADWATER, Gloria, VREDENBURGH, James J, COLVIN, . Michael, PETERS, William P, JONES, Roy B, HALL, Jeff, MARKS, Jeffrey R

“…To evaluate associations between patient survival, pharmacokinetics, and drug metabolism-related genetic polymorphisms in patients receiving a combination…”
Get full text

Prospective, Randomized Comparison of High-Dose Chemotherapy With Stem-Cell Support Versus Intermediate-Dose Chemotherapy After Surgery and Adjuvant Chemotherapy in Women With High-Risk Primary Breast Cancer: A Report of CALGB 9082, SWOG 9114, and NCIC MA-13 by Peters, William P, Rosner, Gary L, Vredenburgh, James J, Shpall, Elizabeth J, Crump, Michael, Richardson, Paul G, Schuster, Michael W, Marks, Lawrence B, Cirrincione, Constance, Norton, Larry, Henderson, I C, Schilsky, Richard L, Hurd, David D

“…The prognosis for women with primary breast cancer involving multiple axillary nodes remains poor. High-dose chemotherapy with stem-cell support produced…”
Get full text

Impact of High-Dose Chemotherapy on the Ability to Deliver Subsequent Local–Regional Radiotherapy for Breast Cancer: Analysis of Cancer and Leukemia Group B Protocol 9082 by Marks, Lawrence B., M.D, Cirrincione, Constance, M.S, Fitzgerald, Thomas J., M.D, Laurie, Frances, Glicksman, Arvin S., M.D, Vredenburgh, James, M.D, Prosnitz, Leonard R., M.D, Shpall, Elizabeth J., M.D, Crump, Michael, M.D, Richardson, Paul G., M.D, Schuster, Michael W., M.D, Ma, Jinli, M.D, Peterson, Bercedis L., Ph.D, Norton, Larry, M.D, Seagren, Steven, M.D, Henderson, I. Craig, M.D, Hurd, David D., M.D, Peters, William P., M.D

“…Purpose To report, from Cancer and Leukemia Group B Protocol 9082, the impact of high-dose cyclophosphamide, cisplatin, and BCNU (HD-CPB) vs. intermediate-dose…”
Get full text

Association of High-dose Cyclophosphamide, Cisplatin, and Carmustine Pharmacokinetics with Survival, Toxicity, and Dosing Weight in Patients with Primary Breast Cancer by PETROS, William P, BROADWATER, Gloria, BERRY, Donald, JONES, Roy B, VREDENBURGH, James J, GILBERT, Colleen J, GIBBS, John P, COLVIN, O. Michael, PETERS, William P

“…This report investigates relationships between the pharmacokinetics and pharmacodynamics of high-dose alkylators used for the treatment of primary breast…”
Get full text

A phase 1 study of systemic ADH‐1 in combination with melphalan via isolated limb infusion in patients with locally advanced in‐transit malignant melanoma by Beasley, Georgia M., McMahon, Nicole, Sanders, Gretchen, Augustine, Christina K., Selim, Maria A., Peterson, Bercedis, Norris, Robin, Peters, William P., Ross, Merrick I., Tyler, Douglas S.

“…BACKGROUND: Isolated limb infusion with melphalan is a well‐tolerated treatment for patients with in‐transit extremity melanoma with an approximately 30%…”
Get full text

High‐Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation in the Treatment of Breast Cancer by Peters, William P., Dansey, Roger D., Klein, Jared L., Baynes, Roy D.

“…Each year in the USA, 180,000 new cases of breast cancer are diagnosed and about 44,000 women die of the disease. Current primary treatment consists of…”
Get full text

Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma by de Lima Lopes, Gilberto, Dicksey, Jennifer S., Peters, William P., Palalay, Melvin, Chang, Alex Y.

“…Purpose Eniluracil (EU) is a potent dihydropyrimidine (DPD) inhibitor, which improves the oral bio-availability of 5-fluorouracil (5-FU) and may overcome…”
Get full text

Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma: Pooled analysis of 2805 patients by BRIA, Emilio, GIANNARELLI, Diana, FELICI, Alessandra, PETERS, William P, NISTICO, Cecilia, VANNI, Barbara, CUPPONE, Federica, COGNETTI, Francesco, TERZOLI, Edmondo

“…Abstract BACKGROUND The magnitude of the benefit of adding taxanes to anthracyclines in first‐line chemotherapy for metastatic breast carcinoma is still…”
Get full text

Evaluation of symptom distress in a bone marrow transplant outpatient environment by Lawrence, C C, Gilbert, C J, Peters, W P

“…To measure patient perceptions of autologous bone marrow transplantation (ABMT)-associated symptoms in the outpatient setting, assess the efficacy of the…”
Get more information

Transforming Growth Factor β as a Predictor of Liver and Lung Fibrosis after Autologous Bone Marrow Transplantation for Advanced Breast Cancer by Anscher, Mitchell S, Peters, William P, Reisenbichler, Herbert, Petros, William P, Jirtle, Randy L

“…Hepatic veno-occlusive disease is a serious consequence of high-dose chemotherapy or radiotherapy combined with bone marrow transplantation for neoplasia; it…”
Get full text

Cost‐effectiveness and lung cancer clinical trials by Du, Wei, Reeves, Jaxk H., Gadgeel, Shirish, Abrams, Judith, Peters, William P.

“…BACKGROUND Lung cancer is the leading cause of cancer death in the U.S., with an estimated annual economic burden of $5 billion. Clinical trials offer…”
Get full text

Taxanes with anthracyclines as first‐line chemotherapy for metastatic breast carcinoma by Bria, Emilio, Giannarelli, Diana, Felici, Alessandra, Peters, William P., Nisticò, Cecilia, Vanni, Barbara, Cuppone, Federica, Cognetti, Francesco, Terzoli, Edmondo

“…BACKGROUND The magnitude of the benefit of adding taxanes to anthracyclines in first‐line chemotherapy for metastatic breast carcinoma is still unclear. The…”
Get full text

Cost analysis of pancreatic carcinoma treatment by Du, Wei, Touchette, Daniel, Vaitkevicius, Vainutis K., Peters, William P., Shields, Anthony F.

“…BACKGROUND Pancreatic carcinoma is a major health issue and financial burden to society. To improve the quality and efficiency of care delivered, it is…”
Get full text

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation by Brandt, S J, Peters, W P, Atwater, S K, Kurtzberg, J, Borowitz, M J, Jones, R B, Shpall, E J, Bast, Jr, R C, Gilbert, C J, Oette, D H

“…Recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) has been reported to increase the leukocyte count in subhuman primates subjected…”
Get more information

Variation in Approval by Insurance Companies of Coverage for Autologous Bone Marrow Transplantation for Breast Cancer by Peters, William P, Rogers, Mark C

“…During the current debate on health care reform, access to state-of-the-art care for serious illness has been stressed as an essential part of universal health…”
Get full text

Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer by GILBERT, C. J, PETROS, W. P, PETERS, W. P, VREDENBURGH, J, HUSSEIN, A, ROSS, M, RUBIN, P, FEHDRAU, R, CAVANAUGH, C, BERRY, D, MCKINSTRY, C

“…Both ondansetron and cyclophosphamide are thought to be metabolized by hepatic microsomal processes. The purpose of this study was to evaluate the potential…”
Get full text

High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: past or future? by Baynes, R D, Dansey, R D, Klein, J L, Hamm, C, Campbell, M, Abella, E, Peters, W P

“…Given that each year in the United States 180,000 new cases of breast cancer are diagnosed, with about 44,000 women succumbing to the disease, and that breast…”
Get more information

Cooperative groups are not by Peters, William P

Get more information

Impact of Consolidation Radiotherapy in Patients With Advanced Breast Cancer Treated With High-Dose Chemotherapy and Autologous Bone Marrow Rescue by CARTER, D. L, MARKS, L. B, BEAN, J. M, BROADWATER, G, HUSSEIN, A, VREDENBURGH, J. J, PETERS, W. P, PROSNITZ, L. R

“…To examine the impact of consolidation radiotherapy (RT) after high-dose chemotherapy with autologous bone marrow rescue (HDC) in patients with advanced breast…”
Get full text